Bexen Bioservices and VIVEbiotech collaborate in the development of medicines for human use

Bexen Bioservices, pioneer in the management and storage of biological samples and thermolabile medicines for human use for the biotechnology and biopharmaceutical sector, and VIVEbiotech, European leader in the development and manufacture of lentiviral vectors, have reached an agreement that strengthens the security and management in the storage process of these valuable tools used in gene therapy and in the research of medicines for human use.

The new agreement reinforces the link between two pioneering companies in the biotechnology sector in the area, as each of them is a clear reference in its field. The collaborations of companies dedicated to biotechnology highlight the solid network of companies dedicated to the health sector that has been generated in recent years and which is experiencing a buoyant moment.

The production of lentiviral vectors under EMA and FDA standards by VIVEBiotech, trusted by more than 40 biotech companies, will be managed and stored by Bexen Bioservices in its installations with the latest technology. Lentiviral vectors produced by VIVEbiotech are administered both ex-vivo and in-vivo to treat various disorders, such as hematological and solid cancers, and rare diseases.

Bexen Bioservices has 222 m2 of installations with a capacity to store more than 19 million samples and medicines, divided into 2 deep-freezing rooms with the latest technology equipment (range from -20°C to -80°C) and 2 freezing chambers at -20°C and -30ºC.

Bexen Bioservices services are endorsed by the most demanding certifications such as ISO 9001, ISO 14001, GDP and is duly registered as an authorized warehouse for thermolabile medicines for human use.